CD10 antigen is a 100-kDa-cell surface zinc metalloendopeptidase expressed in a variety of normal and neoplastic lymphoid and nonlymphoid tissues including melanomas. It was recently shown that metastatic melanomas express more CD10 than primary tumors. We evaluated CD10 expression in tumor and stromal cells in 70 biopsies with primary and 28 with metastatic malignant melanomas. Ki-67, Bcl-2, and Bax were also examined to investigate whether CD10 expression is associated with tumor proliferation index or factors of apoptosis. Formalin-fixed/paraffin-embedded tissues were studied by immunohistochemistry. More advanced primary tumors had higher CD10 expression in the tumor cells (r ¼ 0.27, P ¼ 0.03 for Clark levels and r ¼ 0.29, P ¼ 0.02 for Breslow) and higher Ki-67 proliferation fraction (r ¼ 0.32, P ¼ 0.007 for Clark levels and r ¼ 0.32, P ¼ 0.001 for Breslow). Similarly, CD10 expression in the intratumoral stromal cells was also higher in primary tumors with higher Clark level (P ¼ 0.04, linear-by-linear association) and tumor thickness according to Breslow (r ¼ 0.33, P ¼ 0.01). The presence of CD10 þ peritumoral stromal cell cuffs was also positively associated with tumor thickness according to Breslow (r ¼ 0.27, P ¼ 0.05). Also, expression of CD10 and Ki-67 were significantly higher in metastatic than in primary tumors (P ¼ 0.01 and 0.02 respectively), but Bcl-2 expression was higher in primary melanomas (P ¼ 0.02). We conclude that CD10 expression in malignant melanoma is associated with tumor progression.
The biology and natural history of melanocytic tumors are still incompletely understood. Several clinical and routine histological factors of primary melanomas with prognostic significance have been described, that is, tumor thickness according to Breslow, Clark levels, ulceration, localization, presence of tumor-infiltrating lymphocytes, gender, and patients' age. 1 By far, the most significant and consistent prognostic factor in all series over the past 20 years is Breslow thickness of the primary melanoma. 2 Kanitakis et al 3 have recently found that CD10 is more frequently expressed in metastatic than in primary melanoma. Carrel et al 4 also found that CD10 expression in melanoma cells is higher in primary tumors larger than 3 mm.
CD10 is a 90-110-kDa cell surface zinc-dependent metalloprotease that has been called neutral endopeptidase, enkephalinase, neprilysin, and common acute lymphoblastic leukemia antigen. Besides hematopoietic tissue, various benign and malignant nonhematopoietic tissues were also found to express CD10. [5] [6] [7] [8] [9] [10] CD10 is known to regulate biological activities of peptide substrates by reducing the local concentrations available for receptor binding and signal transduction.
11 CD10 may also play an important role in maintenance of homeostasis, neoplastic transformation, and tumor progression. [12] [13] [14] Recent works suggested that CD10 expression in cancer cells could have a role both in apoptosis and proliferation, [15] [16] [17] while CD10 expression in intratumoral stromal cells may also contribute to tumor progression.
Programmed cell death, apoptosis, is a physiological mechanism of cell death that plays an important role during development, metamorphosis, and organ involution in many diseases, including cancer. 19 Regulation of apoptosis is a complex process and involves a number of genes, including Bcl-2, Bax, and related family members. [19] [20] [21] Bcl-2, the protein product of the Bcl-2 gene, is a member of the Bcl-2 family of proteins that play a crucial role in a complex mechanism of apoptosis. The Bcl-2 family is divided into two subfamilies: the proapoptotic family (ie Bax, Bak, Bik, Bad), which induce apoptosis, and the antiapoptotic family (ie Bcl-2, Bcl-x L , Bcl-w), which protect cells from apoptosis. 22 Bax gene product, an intracellular partner of Bcl-2, first identified by coimmunoprecipitation with Bcl-2, is a 21-kDa protein with 21% homology to Bcl-2. Expression of Bax does not block apoptosis; instead, it seems to inhibit Bcl-2 function, perhaps by forming Bcl-2/Bax heterodimers or by competing with other Bcl-2 target. 23 It is suggested that the Bcl-2/Bax ratio may be important in regulating the nature of the apoptotic response; if Bax predominates, apoptosis is accelerated, and the antiapoptotic activity of Bcl-2 is antagonized.
Expression of Bcl-2 family members in melanoma metastases, primary melanomas, naevi and normal tissue samples has been described, [24] [25] [26] [27] but seems to be somewhat controversial as both overexpression and reduced expression have been reported. 28 Their role in the process of malignant transformation of melanocytes has been questioned. No prognostic value of Bcl-2 expression was found by Loggini et al; 29 however, a strong indication of a correlation between tumor thickness and Bcl-2 expression in nodular malignant melanomas has also been reported. 30 Our study explores CD10 expression in primary and metastatic melanoma and its association with proliferation rate (Ki-67) and expression of Bcl-2 and Bax.
Materials and methods
We studied formalin-fixed, paraffin-embedded tissue sections from 70 primary and 28 metastatic melanomas that were randomly collected from the archives of the pathology department, The Norwegian Radium Hospital. The median age of the patients was 62 years (range 19-93 years). Of the primary tumors, 53 were classified as superficial spreading and 17 as nodular. Distribution of Clark levels was as follows: 19% were Clark I, 36% Clark II, 23% Clark III, and 22% Clark IV. The primary tumor thickness median was 1.50 mm (range 0.30-7.00 mm).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was cut at 5 mm, dried overnight at 601C and deparaffinized in xylene. Subsequently, the sections were rehydrated through graded alcohols into water. Heat-induced epitope retrieval was achieved by boiling sections in the EDTA buffer at pH 8.9 in the Electrolux microwave oven (Stockholm, Sweden) at 1000 W for 20 min (4 Â 5 min). After boiling, the sections were allowed to cool at room temperature for 20 min, rinsed thoroughly with water and placed in Tris-buffered saline (TBS) for 5 min. Endogenous peroxidase was blocked with peroxidase block solution provided in the EnVison þ s kit (DakoCytomation, Glostrup, Denmark) for 5 min and slides rinsed/washed with TBS. Primary antibodies used in the study are listed in Table 1 . The visualization was performed using EnVision þ s (DakoCytomation, Glostrup, Denmark) method according to the manufacturer's instructions. Appropriate positive and negative controls were used. Expression of CD10, Bcl-2, and Bax in the tumor cells was quantified using H-score (histoscore) system, according to the method described by McCarty Jr et al, 31 which considers both the intensity and percentage of cells staining at each intensity. Cells are counted by using Â 400 magnification and a cell counter. The score was calculated as follows:
. Ki-67 proliferation fraction was determined by counting the percent of the positive cells in 400 cells using a cell counter. CD10 expression in intratumoral fibroblast-like cells and peritumoral fibroblast-like cells was evaluated only in the primary tumors. The number of positive cells was visually estimated and stratified into four groups (0 ¼ negative, 1 ¼ weakly, 2 ¼ moderate, and 3 ¼ strong expression).
Statistical Methods
Differences in antigen expression between primary and metastatic tumors were analyzed with the Mann-Whitney U-test. The association between the intensity of expression with depth of invasion (Clark levels); tumor thickness according to Breslow and diameter of tumors was studied with the 
Results
Association between Primary Melanoma Size and Expression of CD10, Bcl-2, Bax, and Ki-67 Proliferation Fraction
Distribution of H-scores for CD10, Bcl-2, and Bax is given in Table 2 . The results of CD10 expression and Ki-67 expression are illustrated in Figure 1a -f. CD10 expression in primary melanomas as evaluated by H-score is detailed in Table 3 . When 10% cutoff point was used, 22% ( 
Differences between Primary and Metastatic Melanoma
The results are summarized in Table 6 . At 10% cutoff point, 61% (11/28) metastatic tumors expressed CD10. The level of CD10 expression ( Figure  3a , P ¼ 0.01) and Ki-67 expression (Figure 3b , P ¼ 0.02) were significantly higher in metastatic than primary tumors (Figure 1c and d) . However, Bcl-2 had higher expression in the primary melanoma ( Figure 3a , P ¼ 0.02). Similarly, Bcl-2/Bax ratio was higher in the primary tumors (P ¼ 0.006).
CD10, Bcl-2, and Bax Expression in Benign Looking Skin
In the normal looking skin surrounding tumors, CD10 immunoreactivity was seen in hair follicles, eccrine and sebaceous glands as well as in endothelium of blood vessels, large nerves, and generally scant slender fibroblast-like cells in the dermis. In the normal epidermis, Bcl-2 expression was confined to basal keratinocytes that exhibited cytoplasmic staining with perinuclear enhancement. The suprabasal keratinocytes uniformly were Bcl-2 negative. Bcl-2 reacted strongly with scattered melanocytes in the basal layer of the skin and the hair matrix. Lymphocytes in the dermis and epidermis also expressed Bcl-2. The proapoptotic Bax protein was present in normal epidermis and its appendages, with the suprabasal compartment being stained more strongly than basal keratinocytes. Ki-67 positivity in normal human epidermis was mainly restricted to the suprabasal cell layers of the epidermis.
Discussion
CD10 expression has been reported in six of 15 cultured melanoma cells lines, 32 in malignant melanoma of the uvea and conjunctiva 33 and in cutaneous melanomas. 3, 4, 9, 32, 33 Overall expression of CD10 in cutaneous melanoma is reported to be about 40-50%. However, Carrel et al 4 and Kanitakis et al, 3, 34 found higher expression of CD10 in metastatic tumors. Carrel et al 4 also showed that expression of CD10 is higher in primary melanomas larger than 3 mm. Our study confirms these previous results, but also elaborates observations on CD10 expression in primary melanoma with regard to higher CD10 expression in higher Clark levels and larger Breslow thickness of the tumor. Hence, CD10 expression in melanoma cells appears to be associated with tumor progression. Interestingly, in carcinomas of the lung 35 and kidney, 36 expression of CD10 is downregulated in comparison with benign tissues, but CD10 expression was evaluated only in primary tumors and was not compared to CD10 expression in metastatic lesions.
Even though the exact role of CD10 is currently not known, our study suggests that CD10 expression in malignant melanoma significantly correlates with increased proliferation of melanoma cells. Recently, an association between CD10 expression and increased proliferation was found in diffuse large Bcell lymphoma by Bai et al. 37 In the same study, the 
Figure 1
Only rare primary melanomas had strong expression of CD10 (anti-CD10, magnification Â 100) (a). Such cases were associated with much higher proliferation rate than CD10-negative primary melanomas (anti-Ki-67, magnification Â 100) (b). The strongest expression of CD10 was found in metastatic melanomas, particularly those metastatic to lymph nodes (anti-CD10, Â 100) (c). Metastatic melanomas with strong CD10 expression also had higher proliferation rate than those with weak or no CD10 expression (anti-Ki-67, magnification Â 100) (d). CD10 in malignant melanoma N Bilalovic et al authors also found that CD10 expression was associated with higher apoptotic index. We have not investigated the apoptotic index in our study, but observed that CD10 expression had a negative correlation with Bcl-2 expression and a positive correlation with Bax expression, which is in accordance with the results observed by Bai et al.
37
Our findings that Bcl-2 is more expressed in primary than in metastatic melanomas and that Bcl-2 has an inverse correlation with proliferation fraction are in accordance with previous reports. 38, 39 Bcl-2 is best known for its function as an antiapoptotic protein, but Liang et al 40 just reported that Bcl-2 mediates induction of neural differentiation and decreases expression of several proliferation-related genes in PC12 neural crest tumor cells. Accordingly, it may be plausible that loss of Bcl-2 expression in malignant melanoma may reflect loss of differentiation. Further studies are needed to investigate this possibility. Interestingly, such relationship between degree of cell differentiation and proliferation is also reported in lymphoid tissues. Low-grade follicular lymphomas regularly express high levels of Bcl-2 and have very low proliferation rate, while grade 3 follicular lymphomas frequently have low or no expression of Bcl-2 and also have generally higher proliferation rate. [41] [42] [43] The invasive and/or metastatic potential of several types of cancer cells is regulated by interactions with stromal cells, which involve stimulatory and inhibitory factors that regulate such functions as cellular adhesion, migration, and gene expression. [44] [45] [46] It was postulated that due to structural similarities of CD10 to matrix metalloproteinases (MMPs), CD10 could create a microenvironment that facilitates cancer cell invasion and metastasis. 47, 48 The role of CD10 expression in benign stromal cells was so far investigated only in breast carcinoma. Iwaya et al 18 showed that CD10 is expressed by the stromal cells within the area of invasive ductal carcinoma, but not in the stromal cells of normal breast or noninvasive carcinoma. Our observation that CD10 is expressed in stromal cells of more advanced primary melanomas and their association with higher proliferation rate suggests that stromal cells may also have an important role in progression of malignant melanoma.
In conclusion, more advanced melanomas express more CD10, both in melanoma cells and fibroblastlike stromal cells.
